

## Steatotic livers. Can we use them in OLTX? Outcome data from a prospective baseline liver biopsy study

Mauricio Gabrielli,<sup>\*,||</sup> Fabrizio Moisan,<sup>\*,||</sup> Marcela Vidal,<sup>†</sup> Ignacio Duarte,<sup>†</sup> Macarena Jiménez,<sup>\*</sup> Guillermo Izquierdo,<sup>\*</sup> Pilar Domínguez,<sup>\*</sup> Javier Méndez,<sup>‡</sup> Alejandro Soza,<sup>\*,§</sup> Carlos Benitez,<sup>\*,§</sup> Rosa Pérez,<sup>\*,§</sup> Marco Arrese,<sup>\*,§</sup> Juan Guerra,<sup>\*,†</sup> Nicolás Jarufe,<sup>\*,||</sup> Jorge Martínez<sup>\*,||</sup>

\* Liver Unit, Departments of <sup>†</sup>Pathology, <sup>§</sup> Gastroenterology and <sup>||</sup> Surgery, School of Medicine. Pontificia Universidad Católica de Chile, Santiago, Chile.  
<sup>‡</sup> Corporación del Trasplante, Santiago, Chile.

### ABSTRACT

**Introduction.** Steatotic livers have been associated with greater risk of allograft dysfunction in liver transplantation. Our aim was to determinate the prevalence of steatosis in grafts from deceased donors in Chile and to assess the utility of a protocol-bench biopsy as an outcome predictor of steatotic grafts in our transplant program. **Material and methods.** We prospectively performed protocol-bench graft biopsies from March 2004 to January 2009. Biopsies were analyzed and classified by two independent pathologists. Steatosis severity was graded as normal from absent to < 6%; grade 1: 6-33%; grade 2: > 33-66% and grade 3: > 66%. **Results.** We analyzed 58 liver grafts from deceased donors. Twenty-nine grafts (50%) were steatotic; 9 of them (16%) with grade 3. Donor age ( $p < 0.001$ ) and BMI over 25 kg/m<sup>2</sup> ( $p = 0.012$ ) were significantly associated with the presence of steatosis. There were two primary non-functions (PNF); both in a grade 3 steatotic graft. The 3-year overall survival was lower among recipients with macrovesicular steatotic graft (57%) than recipients with microvesicular (85%) or non-steatotic grafts (95%) ( $p = 0.026$ ). **Conclusion.** Macrovesicular steatosis was associated with a poor outcome in this series. A protocol bench-biopsy would be useful to identify these grafts.

**Key words.** Fatty liver. Liver steatosis. Liver transplantation. Organ injury. Transplantation.

### INTRODUCTION

The use of steatotic livers for liver transplantation (LT) has been associated with a greater risk of complications due to higher rates of preservation injury and allograft dysfunction.<sup>1-2</sup> However, the growing number of patients on waiting lists for LT and the shortage of organ donors have forced many centers to accept extended criteria for graft selection, moving the limit of acceptance for grafting beyond the classic 33% of liver steatosis.<sup>3</sup> Since nonalcoholic fatty liver disease (NAFLD) has become a common condition in the general population,<sup>4</sup> reaching figures of up to 30% of prevalence, the decision as to whether to use a steatotic graft is a

common difficulty for the liver transplant team. This is particularly true in countries with a high prevalence of subjects with Hispanic genetic background, since the prevalence of NAFLD is higher among these subjects.<sup>5</sup>

Although a protocol-bench biopsy is the best way to assess the degree of steatosis and the presence of necroinflammatory changes in liver grafts, this procedure is not routinely used in LT.<sup>6</sup> The aim of the present study was to determinate the prevalence of steatosis in grafts from deceased donors in Chile and to assess the utility of a protocol-bench biopsy as an outcome predictor when using steatotic and non-steatotic grafts for LT.


### MATERIAL AND METHODS

From March 2004 to January 2009, we prospectively performed a protocol-bench graft biopsy for every LT performed in our institution. Specimens obtained on bench were fixed in buffered formalin, paraffin embedded, and stained with hematoxylin-eosin. All liver biopsies were reassessed by two in-

Correspondence and reprint request: Jorge Martínez, M.D.  
Liver Unit, Departamento de Cirugía Digestiva, Facultad de Medicina, Pontificia Universidad Católica de Chile. Marcoleta 367, Santiago, Chile.  
Tel.: 56 2354-3462. Fax: 56 2638-2793  
E mail: jamartin@med.puc.cl

Manuscript received: February 9, 2012.  
Manuscript accepted: February 23, 2012.

dependent experienced pathologists with no knowledge of the original pathology report. Degree of steatosis was assessed according to Kleiner<sup>7</sup> and Brunt.<sup>8</sup> Macro- and microsteatosis were evaluated semi-quantitatively. Severe steatosis (grade 3) was defined as the presence of fat droplets in more than 66% of hepatocytes in the graft biopsy; moderate (grade 2) and mild (grade 1) steatosis were defined as the presence of fat droplets between 34-66% and 6-33% respectively, following current recommenda-



**Figure 1.** A. Severe steatosis: small, medium and large fat vacuoles in over 66% of hepatocytes (hematoxylin and eosin x40). B. Moderate steatosis: small, medium and large fat vacuoles in approximately 60% of hepatocytes (Hematoxylin and eosin x40). C. Mild steatosis: medium and large fat vacuoles in approximately 10% of hepatocytes (hematoxylin and eosin x40). D. Normal (non-steatotic) liver. No cytoplasmic fat vacuoles are seen (hematoxylin and eosin x40).


tions<sup>8</sup> (Figures 1A-1C). The presence of less than 6% of steatosis was considered normal (Figure 1D). Macrovesicular/microvesicular steatosis biopsies were classified as predominantly macrovesicular or predominantly microvesicular (Figure 2A-2C). Specimens, predominantly microvesicular on hematoxylin-eosin were also stained with the PAS/PAS-diastase method. One case with steatohepatitis was not considered in this study because this graft was discharged. No fibrosis other than grades 0 or 1A was found.

The outcomes of patients who received steatotic grafts were compared to those of a group of patients grafted with non-steatotic livers. Surgeons did not have detailed pathology reports before at the time of transplantation. Thus, decisions about graft implantation were based mainly on macroscopic aspects of the liver and the urgency of LT indications.

#### Donor data

Organ procurement was performed either with aortic and portal perfusion, or only aortic perfusion, depending on the surgeon's preference. Preservation solutions were either Histidine-Tryptophan-Ketoglutarate (Custodiol<sup>TM</sup>) or University of Wisconsin (Viaspan<sup>TM</sup>).

In addition to steatosis, the following donor or graft data were recorded: occurrence of cardiac arrest, donor age ( $\geq 60$  years), high vasoactive drug requirement (2 or more drugs), length of stay in intensive care unit (more than 4 days) and cold ischemic time (more than 10 h). The donor's cause of death was also analyzed. Donor obesity was defined as BMI  $\geq 30$  kg/m<sup>2</sup>.



**Figure 2.** A. Macrovesicular steatosis: one or a few well-demarcated fat vacuoles displace the nucleus to the edge of the cell (PAS-diastase, original magnification x400). B. Microvesicular steatosis: multiple, well-demarcated cytoplasmic microvacuoles surround the nucleus without altering their location (PAS-diastase, original magnification x400). C. microvesicular steatosis: frozen section stained for lipid (Oil-Red-O, original magnification 400x).

### Recipient data

Demographic data, indication of transplantation (Urgent/Elective), and clinical status assessed by the Child-Pugh and MELD scores of all recipients were recorded in the local database.

### Postoperative outcome

Liver allograft function was evaluated clinically and through the use of selected biochemical parameters. Liver function tests were measured on arrival at the ICU. Initial poor graft function (IPGF) was defined as an increase in aspartate aminotransferase (AST) > 1,500 UI/L and prothrombin time exceeding 20 sec during the first postoperative week. Primary non-function (PNF) was defined as poor function of the allograft culminating in either the death of the recipient or the need for re-transplantation, in the absence of any vascular complication.

### Statistical analysis

For survival calculations we included the variables of cold ischemic time, preservation solution, warm ischemic time, sex, BMI, in a multivariate analysis. Survival analyses were performed using

the Kaplan-Meier method. Comparison among groups was carried out using the logrank test. Continuous variables were compared using the t test for independent samples. Categorical data were compared using the chi-square test. Values of  $p < 0.05$  were considered to be significant. Calculations were done with the SPSS statistical software package (version 19.0).

## RESULTS

Fifty-nine liver graft biopsies were obtained and analyzed during the study period. In one case the graft was discharged, because a call warning of pathologist about a severe steatosis and steatohepatitis observed. The surgical team decided to not proceed with the transplant procedure. Then, the results were analyzed on 58 grafts biopsied and implanted. There were no clinical differences among most demographic characteristics of recipients and donors between steatotic and non-steatotic grafts (Table 1). The only 2 characteristic investigated associated with steatotic graft were BMI (23 vs. 28 kg/m<sup>2</sup>,  $p = 0.011$ ) and donor age (35 vs. 48 years,  $p < 0.001$ ). BMI among over 25 kg/m<sup>2</sup> donors was significantly associated with the presence of steatosis ( $p = 0.012$ ). Only five patients with steatosis had a BMI  $\geq 30$  m/kg<sup>2</sup>.

**Table 1.** Demographic characteristics of cases.

Characteristics of recipient, donor and graft	Non-steatosis or < 6% (n = 29)	Steatosis $\geq$ 6% (n = 29)	p value
Recipient age (years)	54 (16-71)	55 (20-67)	0.675
Recipient sex (male)	17 (59%)	22 (76%)	0.263
MELD score	18 (8-38)	18 (6-40)	0.549
Urgent transplant	9 (31%)	9 (31%)	1
Retransplant	3 (10%)	1 (3%)	0.611
Donor age (years)	35 $\pm$ 12	48 $\pm$ 11	< 0.001
Donor sex (male)	17 (65%)	16 (62%)	1
Donor BMI	23 $\pm$ 2	28 $\pm$ 3	0.012
ABO group			
Identical	27 (92%)	26 (89%)	1
Compatible	2 (8%)	3 (11%)	
Preservation solution			
WU	13 (43%)	9 (26%)	0.300
HTK	16 (57%)	20 (74%)	
Donor BMI	23 $\pm$ 2	28 $\pm$ 3	0.012
Cold ischemic time (h)	9.3 $\pm$ 2.8	9.9 $\pm$ 2.5	0.429
Warm ischemic time (min)	36 (15-100)	38 (20-79)	0.829
Red blood cell transfusion (unit)	3 (0-18)	4 (0-16)	0.117
Reperfusion injury (moderate or severe)	6 (21%)	9 (32%)	0.546

MELD: model for end-stage liver disease. BMI: body mass index. WU: Wisconsin University. HTK: histidine-tryptophan-ketoglutarate. Values expressed in means  $\pm$  standard deviation or in medians (ranges) according to their distribution. P value calculated using chi square or Fisher test for categorical variable and t-test or Mann-Whitney test according to their distribution for continuous variable.

**Table 2.** Donor and recipient features of each graft with steatosis.

Donor data			Recipient Data			
Age (yr)	CIT (h)	Risk factor*	Steatosis (%)	Drop (Mas or Mis)	Etiology	One year survival
52	8.3	Cardiac arrest	90	Mas	NASH	No
43	14.1	Ischemic time	90	Mas	NASH	Yes
54	7.2	None	90	Mas	NASH	LFU
56	-	Cardiac arrest	85	Mis	NASH	Yes
41	11.9	Ischemic time	85	Mis	Unknown	Yes
28	9.2	None	80	Mis	Unknown	No
46**	9.4	Vasopressor, cardiac arrest	80	Mas	ALF	No
58	9.2	None	70	Mis	ALF	Yes
33**	6.34	None	70	Mas	ALF	No
55	9.2	Cardiac arrest	65	Mas	AH	Yes
49	7.3	Vasopressor	60	Mas	Alcohol	Yes
61	10.3	Age, ischemic time	60	Mas	Alcohol	Yes
47	12.2	Ischemic time	60	Mas	Unknown	Yes
37	-	None	60	Mis	HM	Yes
29	14.4	Ischemic time	50	Mis	Alcohol	Yes
62	4.4	ICU stay, age	35	Mas	NASH	Yes
38	11.2	Cardiac arrest, ischemic time	30	Mas	NASH	Yes
45	9.2	None	30	Mis	Alcohol	LFU
38	3.4	None	25	Mas	HCV	Yes
41	8.4	Cardiac arrest	20	Mis	ALF	Yes
53	7.4	None	20	Mis	PD	Yes
50	12.9	Ischemic time	20	Mas	Unknown	Yes
62	7	Age	20	Mas	Alcohol	Yes
33	10.1	ICU stay, ischemic time	15	Mis	HCC	Yes
51	11.8	Ischemic time	15	Mis	NASH	Yes
66	10.4	ICU stay, ischemic time, age	10	Mas	HCV	Yes
48	8.2	None	10	Mis	HAT	Yes
61	9.32	None	10	Mis	ALF	LFU
34	8.8	None	10	Mas	HM	Yes

\*Risk factor defined in the methods section. \*\*Primary non-function. LFU: live at follow up. CIT: cold ischemic time. Mas: macrosteatosis. Mis: microsteatosis. ICU: intensive care unit. ALF: acute liver failure. NASH: no-alcoholic steatohepatitis. HCC: hepatocarcinoma. HCV: hepatitis C virus. AH: autoimmune hepatitis. HAT: Hepatic artery thrombosis. PD: polycystic disease. HM: hemochromatosis.

Seventy-two percent of donors with steatotic livers were over 40 years of age *vs.* 38% of donors without steatosis (OR 4.3, IC 95% 1.4-12.9,  $p = 0.008$ ).

Twenty-nine (50%) of the 58 liver grafts analyzed were steatotic livers; 13 (22%) with steatosis grade 1; 7 (12%) with steatosis grade 2 and 9 (16%) with steatosis grade 3. The majority of the donors were male [37 (64%)]. The mean donor age was  $41.4 \pm 14$ .

Fifteen (26%) grafts had macrosteatosis, which was mainly associated with grade 3 steatotic livers ( $p = 0.034$ ). Table 2 lists donor features and recipient outcomes for each graft with steatosis. Grafting of a steatotic liver was significantly associated with an increase in serum levels of aminotransferases greater than 1,500 U/mL ( $p = 0.0001$ ) and was

not associated with a rise of total bilirubin, or with a decrease in prothrombin time.

We observed two PNFs resulting in patient death. These patients were not re-transplanted due to the lack of donor availability. Both had severely (grade 3) steatotic livers; one of them 70% and the other 80% (Table 3). Another patient had an IPGF, requiring a successful re-transplantation after three months. Thirteen patients developed IPGF and eleven of them had a steatotic liver. Patients with macrovesicular steatosis had a significantly higher incidence of IPGF than patients with microvesicular steatosis: 60% *vs.* 17% respectively ( $p < 0.001$ , Chi-Square Test) (Table 4).

When we analyzed the overall survival with the variables of cold ischemic time, preservation solution, warm ischemic time, sex, BMI in a multivaria-

**Table 3.** Features of PNF cases.

Donor data		Recipient Data						
• Case 1								
Sex	Male	Sex	Female					
Age (years)	46	Age (years)	36					
Cause of death	Cardiac arrest	OLT indication	Acute liver failure					
Steatosis (%)	80	Urgency transplant	Yes					
High vasopressor drug requirement	No	Cold ischemic time	9 h and 47 min					
Stay in intensive care unit	3 days	Total ischemia time	10 h and 40 min					
Serum sodium	162 mEq/L	Blood transfusion	2 units					
Serum potassium	4.6 mEq/L	Liver test	AST	ALT	GGT	ALP	Bi T	Bi D
		9 h post LT	10387	3707	114	128	11	8.7
		13 h post LT	10147	4540	163	160	10.3	8.12
• Case 2								
Sex	Male	Sex	Male					
Age (years)	33	Age (years)	35					
Cause of death	VEA	OLT Indication	Acute Liver Failure					
Steatosis (%)	70	Urgency transplant	Yes					
High vasopressor drug requirement	No	Cold ischemic time	6 h and 34 min					
Stay in intensive care unit	1 day	Total ischemia time	7 h 50 min					
Serum sodium	151 mEq/L	Blood transfusion	14 units					
Serum potassium	4.5 mEq/L	No liver test obtained	No bile during operation		Lactic acid raising			
			Dead two hours after transplantation					

OLT: orthotopic liver transplantation. mEq/L: milliequivalents of solute per liter. AST: aspartate aminotransferase. ALT: alanine transaminase. GGT: gamma glutamil transpeptidase. ALP: alkaline phosphatase. Bi T: total bilirubin. Bi D: direct bilirubin. VEA: vascular encephalic arrest.

**Table 4.** Initial poor graft according to type of steatosis.

	Initial poor graft function	
	No	Yes
Non-steatosis	27 (93%)	2 (7%)
Microvesicular	10 (83%)	2 (17%)
Macrovesicular	6 (40%)	9 (60%)


Chi square:  $p < 0.001$ .

te analysis, there was no impact in overall survival. Overall survival at five years follow-up for non-steatotic and livers with more than 66% of steatosis was 95% and 78% respectively ( $p = 0.032$ ) (Figure 3). There are no differences in cold ischemic time between steatotic and non-steatotic livers ( $p = 0.429$ ). Only two deaths occurred among patients who received normal liver grafts during the follow-up, with no graft failure. Causes of death were heart attack

at three months and sepsis due to severe pneumonia at eleven months after LT. The 3-year overall survival was lower among recipients with macrovesicular steatotic graft (57%) than recipients with microvesicular (85%) or non-steatotic grafts (95%) ( $p = 0.026$ ) (Figure 4).

## DISCUSSION


The increasing need for organ grafts has forced liver transplant teams to use extended criteria grafts that do not meet optimal accepted definitions aimed at obtaining the best outcome after transplantation.<sup>9</sup> The combination of multiple risk factors [such as donor age ( $> 55$  years), donor hospital stay ( $> 5$  days), hepatic steatosis, cold ischemia time ( $> 10$  h), and warm ischemia time] seems to be additive in terms of the graft injury occurrence rate.<sup>10</sup> Among these risk factors, steatosis is probably the



**Figure 3.** Survival of patients submitted to an OLT with non-steatotic or < 6% liver grafts vs. steatotic grafts between 6% and 66% vs. over 66%.

most common, raising the question of whether or not to use a steatotic liver. Up to 50% of patients undergoing major liver resection<sup>11</sup> and up to 30% among deceased organ donors had liver steatosis, according to different series.<sup>12-13</sup> In the present study, we found an even higher frequency (50%). This disparity may be due to the different criteria to quantify and qualify liver steatosis. El-Badry, *et al.* showed a significant variability among experts in quantitative and qualitative assessments of the histological features of liver steatosis.<sup>13</sup> The type of biopsy stain used also plays an important role, for example, Sudan-III or toluidine blue are more sensitive in detecting steatosis than hematoxylin-eosine.<sup>14-15</sup> In our study we used only hematoxylin-eosin staining, so we recognize that graft steatosis may be undervalued. Other reasons for this disparity could be related to different donor selection policies, as well as ethnicity, obesity rates and predisposition to NAFLD and alcohol consumption; all factors that may determine the high prevalence of steatosis among Chilean donors.

A number of studies in the 1990s reported that transplantation with livers harboring severe steatosis almost invariably led to PNF. In a recent study McCormack, *et al.*<sup>9</sup> reported a 3-year survival rate of 83% and 84% among patients receiving livers with severe steatosis ( $\geq 60\%$ ), as compared to those who received a normal allograft. In the present study, we observed only 2 PNF, 3.4% of the entire se-



**Figure 4.** Three years survival according to the type of steatotic and non-steatotic grafts.

ries. However, they occurred exclusively in the group with severe steatosis. The two patients urgently required liver replacement and the macroscopic steatotic allografts were the only grafts available in the country. Notably, in general there are few donors per inhabitant in Chile.<sup>16</sup>

We found a 7% incidence of IPGF among non-steatotic grafts vs. 37% among steatotic grafts. Within this latter group, there were no difference in grafts with steatosis  $\leq 33\%$  vs.  $> 33\%$  (39% vs. 35% respectively), in contrast to other series that report higher initial poor function in moderate steatosis.<sup>17-18</sup>

Overall, the observed 3-year rates were 67% and 93% in subjects receiving liver allografts with severe steatosis ( $\geq 66\%$ ) and normal allografts, respectively. Our survival rate is significantly lower than that reported by McCormack, *et al.*,<sup>9</sup> who found a 3-year survival rate of 83% among patients transplanted with grafts with severe steatosis. This difference may be because the MELD scores of recipients in the McCormack study were quite low (mean 12). Moreover, in our study, this subgroup of patients had a rather high mean cold ischemia time ( $10 \pm 2$  h).

Others studies have shown 12-month-survival rates of 58%<sup>19</sup> and 25%<sup>20</sup> among patients receiving grafts with more than 60% macrosteatosis. Our 12-month-survival rate of patients receiving grafts with more than 66% macrosteatosis was 40%, which is in accordance with the other studies.

Specifically, the presence of macrovesicular steatosis is a risk factor of a poor outcome. In our study, we found an increased risk of poor initial function and a lower 3-year-survival rate among patients receiving grafts with macrosteatosis compared to patients who received microsteatosis or non-steatotic grafts. These results are consistent with the results reported by others authors.<sup>21-22</sup>

In a study with 501 liver transplant patients, Spitzer, *et al.*<sup>23</sup> showed that more than 30% macrosteatosis was an independent risk factor associated with a lower one-year graft survival rate (relative risk 1.71). We observed that grafts with > 33% of macrosteatosis had lower one year graft survival than livers with the same proportion of microsteatosis: 70% *vs.* 83% respectively, but this difference did not reach statistical significance.

The issue of using Microvesiculars (MiS) or Macrovesiculars (MaS) fatty livers remains controversial.<sup>24</sup> Some groups have recommended that grafts with more than 30% of macrovesicular steatosis should not be used for LT,<sup>25-26</sup> but on the other hand, a recent study demonstrated that MiS is an independent donor factor influencing graft function, and reported a 100% primary graft non-function rate when severely steatotic grafts with MiS were used for re-transplantation.<sup>27</sup> However, other group have suggested that livers with severe MiS can be safely used for LT.<sup>28</sup>

Our results show that using steatotic grafts was associated with a lower survival rate than the rate with normal allografts. However, we did not find significant differences in patient survival when we compare using mild, moderate or severe steatotic allografts, which very likely is related to the small number of cases in each group.

To our knowledge there is no formal recommendation to perform a liver biopsy with every donor. The present clinical practice is that livers judged to be fatty by the harvesting surgeon are evaluated with histological analysis. Ureña, *et al.*<sup>29</sup> in 1998 stressed that an intraoperative donor biopsy should be performed before graft perfusion with the preservative solution, but procurement teams do not always have all the tools to perform the biopsy at the donor hospital. From our experience, it is easier to execute the graft biopsy on bench at the transplant centre than at donor facilities.

NAFLD affects up to 30% of the population and up to 80% of obese individuals in Western countries.<sup>4,30-31</sup> Despite this, only 23% of liver transplant recipients in the United Network for Organ Sharing (UNOS) have any record of a liver donor biopsy,<sup>14</sup>

even though the majority of liver transplant programs require a graft biopsy before accepting or rejecting the graft.<sup>32</sup>

The risk factors for NAFLD include diabetes mellitus, obesity, hypertriglyceridemia and sedentary life style.<sup>33</sup> In our study, a BMI over 25 was significantly associated with graft steatosis. The other risk factor associated with steatotic liver that we found was a donor age of more than 40 years. Consequently, we believe that a donor age of over 40, donor BMI of over 25 kg/m<sup>2</sup>, and histories of diabetes mellitus and hypertriglyceridemia should be indications of the need for graft biopsy to assess the degree and type of steatosis.

In summary, fatty liver is a prevalent problem that affects the survival of transplant patients, but given the lack of donors in our country, we should not reject livers that are classified as steatotic based only on clinical appraisal in the operating room, making histological assessment necessary. In fact, in this setting, fatty livers up to 50% of steatosis can be used safely.

## ABBREVIATIONS

- **LT:** liver transplantation.
- **NAFLD:** non-alcoholic fatty liver disease.
- **MaS:** macrosteatosis.
- **MiS:** microsteatosis.
- **MELD:** model for end-stage liver disease.
- **FA:** fatty acid.

## FINANCIAL SUPPORT

This work was partially supported by a grant from the Chilean National Fund for Research in Science and Technology (FONDECYT 1110455 and ACT79 to MA).

## CONFLICT OF INTEREST

None of the authors has conflicts of interest to disclose.

## REFERENCES

1. Trevisani F, Colantoni A, Caraceni P, Van Thiel DH. The use of donor fatty liver for liver transplantation: a challenge or a quagmire? *J Hepatol* 1996; 24: 114-21.
2. Adam R, Reynes M, Johann M, Morino M, Astarcioglu I, Kafetzis I, Castaing D, et al. The outcome of steatotic grafts in liver transplantation. *Transplant Proc* 1991; 23: 1538-40.
3. Busuttil RW, Tanaka K. The utility of marginal donors in liver transplantation. *Liver Transpl* 2003; 9: 651-63.

4. Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). *Ann Hepatol* 2009; 8(Suppl. 1): S4-S8.
5. Riquelme A, Arrese M, Soza A, Morales A, Baudrand R, Pérez-Ayuso RM, González R, et al. Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. *Liver Int* 2009; 29: 82-8.
6. Hatta T, Fujinaga Y, Kadoya M, Ueda H, Murayama H, Kurozumi M, Ueda K, et al. Accurate and simple method for quantification of hepatic fat content using magnetic resonance imaging: a prospective study in biopsy-proven non-alcoholic fatty liver disease. *J Gastroenterol* 2010; 45: 1263-71.
7. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology*. 2005; 41: 1313-21.
8. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. *Am J Gastroenterol* 1999; 94: 2467-74.
9. McCormack L, Petrowsky H, Jochum W, Mullhaupt B, Weber M, Clavien PA. Use of severely steatotic grafts in liver transplantation: a matched case-control study. *Ann Surg* 2007; 246: 940-6; Discussion 6-8.
10. Durand F, Renz JF, Alkofer B, Burra P, Clavien PA, Porte RJ, Freeman RB, et al. Report of the Paris consensus meeting on expanded criteria donors in liver transplantation. *Liver Transpl* 2008; 14: 1694-707.
11. Petrowsky H, McCormack L, Trujillo M, Selzner M, Jochum W, Clavien PA. A prospective, randomized, controlled trial comparing intermittent portal triad clamping versus ischemic preconditioning with continuous clamping for major liver resection. *Ann Surg*. 2006; 244: 921-8; Discussion 8-30.
12. Angele MK, Rentsch M, Hartl WH, Wittman B, Graeb C, Jauch KW, Loehe F. Effect of graft steatosis on liver function and organ survival after liver transplantation. *Am J Surg*. 2008; 195: 214-20.
13. Verran D, Kusyk T, Painter D, Fisher J, Koorey D, Strasser S, Stewart G, et al. Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation. *Liver Transpl* 2003; 9: 500-5.
14. El-Badry AM, Breitenstein S, Jochum W, Washington K, Paradis V, Rubbia-Brandt L, Puhan MA. Assessment of hepatic steatosis by expert pathologists: the end of a gold standard. *Ann Surg* 2009; 250: 691-7.
15. Imber CJ, St Peter SD, Lopez I, Guiver L, Friend PJ. Current practice regarding the use of fatty livers: a trans-Atlantic survey. *Liver Transpl* 2002; 8: 545-9.
16. Trasplante Cd. Statistics. Santiago, 2011. Available from: <http://www.trasplante.cl/estadisticas/index.php> [Cited 2011 February, 07].
17. Chen H, Peng CH, Shen BY, Deng XX, Shen C, Xie JJ, Dong W, et al. Multi-factor analysis of initial poor graft function after orthotopic liver transplantation. *Hepatobiliary Pancreat Dis Int* 2007; 6: 141-6.
18. Briceno J, Ciria R, de la Mata M, Rufian S, Lopez-Cillero P. Prediction of graft dysfunction based on extended criteria donors in the model for end-stage liver disease score era. *Transplantation* 2010; 90: 530-9.
19. Nickkholgh A, Weitz J, Encke J, Sauer P, Mehrabi A, Büchler MW, Schmidt J, et al. Utilization of extended donor criteria in liver transplantation: a comprehensive review of the literature. *Nephrol Dial Transplant* 2007; 22(Suppl. 8): viii29-viii36.
20. Noujaim HM, de Ville de Goyet J, Montero EF, Ribeiro CM, Capellozi VL, Crescentini F, Casagrande M, et al. Expanding postmortem donor pool using steatotic liver grafts: a new look. *Transplantation* 2009; 87: 919-25.
21. Halon A, Patrzalek D, Rabczynski J. Hepatic steatosis in liver transplant donors: rare phenomenon or common feature of donor population? *Transplant Proc* 2006; 38: 193-5.
22. Loinaz C, Gonzalez EM. Marginal donors in liver transplantation. *Hepatogastroenterology* 2000; 47: 256-63.
23. Spitzer AL, Lao OB, Dick AA, et al. The biopsied donor liver: incorporating macrosteatosis into high-risk donor assessment. *Liver Transpl* 2010; 16: 874-84.
24. McCormack L, Dutkowski P, El-Badry AM, Clavien PA. Liver transplantation using fatty livers: Always feasible? *J Hepatol* 2010.
25. Selzner M, Clavien PA. Fatty liver in liver transplantation and surgery. *Semin Liver Dis* 2001; 21: 105-13.
26. Nocito A, El-Badry AM, Clavien PA. When is steatosis too much for transplantation? *J Hepatol* 2006; 45: 494-9.
27. Yoong KF, Gunson BK, Neil DA, Mirza DF, Mayer AD, Buckels JA, McMaster P. Impact of donor liver microvesicular steatosis on the outcome of liver retransplantation. *Transplant Proc* 1999; 31: 550-1.
28. Fishbein TM, Fiel MI, Emre S, Cubucku O, Guy SR, Schwartz ME, Miller CM. Use of livers with microvesicular fat safely expands the donor pool. *Transplantation* 1997; 64: 248-51.
29. Urena MA, Ruiz-Delgado FC, Gonzalez EM, Segurolo CL, Romero CJ, García IG, González-Pinto I, et al. Assessing risk of the use of livers with macro and microsteatosis in a liver transplant program. *Transplant Proc* 1998; 30: 3288-91.
30. Chitturi S, Farrell GC, Hashimoto E, Saibara T, Lau GK, Sollano JD. Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. *J Gastroenterol Hepatol* 2007; 22: 778-87.
31. Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ, Goh KL. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? *J Gastroenterol Hepatol* 2007; 22: 788-93.
32. Rey JW, Wirges U, Dienes HP, Fries JW. Hepatic steatosis in organ donors: disparity between surgery and histology? *Transplant Proc* 2009; 41: 2557-60.
33. Dumortier J, Giostra E, Belbouab S, Morard I, Guillaud O, Spahr L, Boillot O, et al. Non-alcoholic fatty liver disease in liver transplant recipients: another story of "seed and soil". *Am J Gastroenterol* 2010; 105: 613-20.